EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Bolt Biotherapeutics, Inc. (BOLT) had EBITDA Margin of -461.23% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$7.70M |
|
$-33.38M |
|
-- |
|
$7.70M |
|
$43.81M |
|
$-36.11M |
|
$2.74M |
|
$-33.38M |
|
$-33.38M |
|
$-33.38M |
|
$-33.38M |
|
$-33.38M |
|
$-33.38M |
|
$-36.11M |
|
$-35.49M |
|
1.87M |
|
1.87M |
|
$-17.85 |
|
$-17.85 |
|
| Balance Sheet Financials | |
$30.26M |
|
$1.25M |
|
$26.49M |
|
$56.75M |
|
$8.44M |
|
$20.13M |
|
$21.81M |
|
$30.24M |
|
$26.50M |
|
$26.50M |
|
$26.50M |
|
1.92M |
|
| Cash Flow Statement Financials | |
$-39.85M |
|
$44.30M |
|
$0.02M |
|
$8.97M |
|
$13.44M |
|
$4.47M |
|
$2.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.59 |
|
-- |
|
-- |
|
0.43 |
|
0.76 |
|
100.00% |
|
-469.30% |
|
-469.30% |
|
|
EBITDA Margin |
-461.23% |
-433.74% |
|
-433.74% |
|
$-38.96M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
-- |
|
-- |
|
-- |
|
-125.92% |
|
-125.92% |
|
-58.81% |
|
-71.57% |
|
$13.80 |
|
$-20.83 |
|
$-21.31 |
|